Primitive quiescent CD34(+) cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib

Primitive quiescent CD34(+) chronic myeloid leukemia (CML) cells are more biologically resistant to tyrosine kinase inhibitors than their cycling counterparts; however, graft-versus-leukemia (GVL) effects after allogeneic stem cell transplantation (SCT) probably eliminate even these quiescent cells...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Yong, Agnes S. M., Keyvanfar, Keyvan, Hensel, Nancy, Eniafe, Rhoda, Savani, Bipin N., Berg, Maria, Lundqvist, Andreas, Adams, Sharon, Sloand, Elaine M., Goldman, John M., Childs, Richard, Barrett, A. John
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2009
Sujets:
Myeloid Neoplasia
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2630272/
https://ncbi.nlm.nih.gov/pubmed/18922853
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-05-158253
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires